Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singaporem and internationally. It provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, central nervous system, anti-infective, epilepsy, allergy and vitamins, anti-histamines, and minerals and supplements under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. The company also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Sanofi India Limited (SANOFI.NS) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 15.91 M | -46,140,380 | 83.3 M | 204.18 M | 148.6 M |
| 2022 | 15.73 M | -116,845,303 | 94.77 M | 246.68 M | 191.74 M |
| 2021 | 24.3 M | -180,203,487 | 99.47 M | 364.48 M | 254.56 M |
| 2020 | 31.57 M | -139,885,725 | 95.2 M | 347.51 M | 218.29 M |
| 2019 | 31.01 M | -133,348,675 | 95.51 M | 386.32 M | 253.54 M |